selitrectinib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2017 (NCT03215511)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Neurotrophic tyrosine kinase receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1- Mol. weight
- 380.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297627 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04771390 | Phase 1 | Feb 16, 2021 | Bayer |
| NCT04275960 | Phase 1 | Feb 28, 2020 | Bayer |
| NCT03215511 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2017 | Bayer, Loxo Oncology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 3 | 2 | 2 | 2017 |
| Loxo Oncology | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1